Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Fractionation assay diagram and accumulation of pathological tau in the postsynaptic compartments in rTg4510 mice.
  • Fig. S2. Synaptic tau does not cosediment with tau aggregates in rTg4510 mice.
  • Fig. S3. Accumulation of pathological tau in the postsynaptic compartments in AD.
  • Fig. S4. Selection of area for quantification of immunoreactivity from human samples.
  • Fig. S5. Pre- and postsynaptic tau from AD brains increased pS202/pT205 tau but not the aggregation of endogenous human tau.
  • Fig. S6. Seed-induced misfolding of endogenous tau can be attenuated by PACAP.
  • Fig. S7. PACAP treatment reduces synaptic tau pathology in rTg4510 mice.
  • Fig. S8. Increased proteasome activity under PACAP-treated conditions.
  • Fig. S9. Effect of PACAP on attenuated tauopathy grouped by treatment and gender.
  • Fig. S10. PACAP treatment attenuates tauopathy.
  • Fig. S11. PACAP treatment reduced pS396/pS404 tau in the hippocampus.
  • Fig. S12. PACAP’s mediated improved cognitive functions showed no gender differences.
  • Fig. S13. Putative mechanism of tau clearance restricted to postsynaptic compartment.
  • Table S1. Human demographics and neuropathological data.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Individual level data.